Deepu Madduri, MD, on Research in Multiple Myeloma This Past Year
The expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.
EP: 1.Study Results Show Promise for Neoantigen Targeting Strategies Such as Peptide Vaccines
EP: 2.Recommendations for Under-Representation of African Americans in Multiple Myeloma
EP: 3.Network Meta-Analysis of Treatment Regimens for Relapsed/Refractory Multiple Myeloma
EP: 4.Genetic Patterns Could Help Doctors Identify Ultra High Risk Patients of Multiple Myeloma
EP: 5.Peter Voorhees, MD on the Progress Made in 2020 For Patients With Multiple Myeloma
EP: 6.Guido Lancman, MD, Discusses Promising Multiple Myeloma Treatments
EP: 7.Lisa La on Areas of Interest Within Multiple Myeloma
EP: 8.Guido Lancman, MD, on Areas of Focus for Multiple Myeloma
EP: 9.Lisa La on Up-and-Coming Multiple Myeloma Research
EP: 10.Deepu Madduri, MD, on Research in Multiple Myeloma This Past Year
In an interview with CancerNetwork®, Deepu Madduri, MD, assistant professor of Medicine (Hematology and Medical Oncology), associate director of Cellular Therapy Service, and director of Clinical Operations with the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discussed the most influential multiple myeloma research that came out of 2020.
Transcription:
At the ASH [Annual Meeting & Exposition] this year, the most influential research, as you saw, were [about] bispecific [agents] or CAR T-cell therapies, right? We’re seeing a lot of changes in immune regulation [regarding] how the immune cells are working and understanding how to use those to target and attack the myeloma cells. There’s going to be a combination of trials and combination therapies that are really going to come up [to the front-line setting to determine] if that will benefit the patients.
Network Meta-Analysis of Treatment Regimens for Relapsed/Refractory Multiple Myeloma
March 24th 2020The researchers indicated that the results could provide additional guidance for the decision-making process when clinicians are deciding on the most appropriate regimen for relapsed and/or refractory multiple myeloma.
Recommendations for Under-Representation of African Americans in Multiple Myeloma
February 14th 2020In a workshop conducted by the FDA and the AACR, working groups came together to address disparities in the representation of African Americans in multiple myeloma clinical trials and to create a set of recommendations in an attempt resolve them.
